Insmed, Inc. $INSM Stake Lifted by Comerica Bank

Key Points

• Comerica Bank increased its holdings in Insmed, Inc. by 70.0% during the first quarter, now owning 290,275 shares worth approximately $22.1 million.
• Analysts have upgraded their target prices for Insmed, with UBS Group raising it to $133.00 and Morgan Stanley increasing it to $144.00, reflecting strong analyst support with a majority rating the stock as a buy.
• Insmed reported a revenue increase of 18.9% year-over-year in its last earnings release, though it reported a loss of ($1.70) per share, missing expectations by ($0.40).

Comerica Bank lifted its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 70.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 290,275 shares of the biopharmaceutical company's stock after purchasing an additional 119,495 shares during the quarter. Comerica Bank owned 0.16% of Insmed worth $22,145,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. M&T Bank Corp grew its stake in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares in the last quarter. Snowden Capital Advisors LLC lifted its holdings in shares of Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after buying an additional 158 shares during the period. Cullen Frost Bankers Inc. lifted its holdings in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Insmed by 6.5% in the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock valued at $287,000 after buying an additional 228 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Insmed by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after purchasing an additional 235 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. UBS Group upped their target price on Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a report on Friday, August 8th. Morgan Stanley upped their target price on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a report on Thursday. Jefferies Financial Group upped their target price on Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. William Blair assumed coverage on Insmed in a research note on Wednesday, August 20th. They issued an "outperform" rating for the company. Finally, HC Wainwright increased their price objective on Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and an average price target of $132.57.

Insmed Stock Performance

Shares of INSM stock opened at $131.88 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $133.56. The stock's 50-day moving average is $107.48 and its two-hundred day moving average is $85.72. The firm has a market cap of $27.88 billion, a P/E ratio of -23.10 and a beta of 0.95.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the company earned ($1.94) earnings per share. The business's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the transaction, the director owned 274,516 shares of the company's stock, valued at approximately $35,549,822. This represents a 3.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider directly owned 89,407 shares in the company, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 539,694 shares of company stock worth $53,144,604 in the last 90 days. Company insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.